Introduction to Dopaminergic Medication

Some evidence shows that these factors can be improved by dopaminergic medication.

To address this question, we tested Parkinson’s patients (n=43) ON and OFF their dopaminergic medication, and compared them to a group of older controls (n=31).

Neuroleptic malignant syndrome (NMS) is a life-threatening neurologic emergency associated with the use of dopamine receptor-antagonist properties or the rapid withdrawal of dopaminergic medications.

The aim of this study was to assess the effects of dopaminergic medication and dual tasking on standing balance in PD by evaluating not only the center of pressure but also muscle cocontraction.

Dopaminergic medications were stopped, and supportive care was initiated in both cases with excellent outcomes.

An approach to the management of early stage PD is discussed, including emerging evidence of the benefits of physical exercise in this condition, and issues to consider in the selection of dopaminergic medication.

The PD-EPVS+ group required higher doses of dopaminergic medications for effective symptom control compared to the PD-EPVS− group.

The performance of PD patients (n = 40) was contrasted with healthy controls (n = 42) across two separate visits (on and off dopaminergic medications) on computerized tasks of perception and aiming to a target at variable stimulus lengths (4, 8, 12 cm).

We characterised the effect of dopaminergic medication on oscillatory whole-brain networks in PD in a time-resolved manner by employing a hidden Markov model on combined STN local field potentials and magnetoencephalography (MEG) recordings from 17 PD patients.

As increased SN activity was also associated (on trend) with higher doses of dopaminergic medication as well as disease duration, the results suggest that learning deficits in PD are associated with disease progression, indexing an increased drive to recruit dopaminergic neurons in the SN, however, unsuccessfully.

For initial treatment of acute migraine, research supports established treatments, particularly antidopaminergic medications and ketorolac and avoidance of opioids, which appears consistent with evaluation of current practice trends.

To address these questions, we measured memory of a learned motor sequence in Parkinson’s patients who were either On or Off their dopaminergic medications.

The introduction of dopaminergic medication failed to restore the effective connectivity modulation observed in the healthy controls.

Neuroleptic malignant syndrome (NMS) is a rare, potentially lethal syndrome known to be related to the initiation of dopamine antagonist medications or rapid withdrawal of dopaminergic medications.

Older adults treated with antidopaminergic medications are at greatest risk for development of tardive dyskinesia.

We replicated the impaired temporal orienting for perceptual discrimination in an independent group of individuals with PD, and showed the impairment was abolished when individuals were on their dopaminergic medication.

Dopaminergic medications can significantly slow down the progression of PD when applied during the early stages.

In this chapter, we link neuropsychiatric symptoms after STN-DBS for PD to the biological effects of electrode implantation, neurostimulation, and adjustments to dopaminergic medication, in the setting of neurodegeneration affecting cortico-striatal connectivity.

In addition to the heterogeneity of ToM tests administered in different studies, depression and dopaminergic medication may also be acting as confounding factors, but there are still insufficient data to support this.

The mesocortical pathway is responsible for the executive function which may change by administration of dopaminergic medication.

Interrogating the model, we further demonstrate that the model is sensitive to dopaminergic medication effects and predominantly uses phase information of the EEG signals.

Contraindicated non-dopaminergic medication was barely prescribed (0.

The evidence of the responsiveness of dopaminergic medication on gait in patients with Parkinson’s disease is contradicting.

Interrogating the model, we further demonstrate that the model is sensitive to dopaminergic medication effects and predominantly uses phase information in the EEG signals.

, action planning, conflict adaptation, inhibition), and that dopaminergic medication may modulate these action control components.

life style changes and pharmacological roles like dopaminergic medications, opioids.

By using the event-related potential (ERP) technique, we sought to: (1) study the temporal dynamics of empathic responses in patients with PD; (2) explore whether dopaminergic medication modulates empathic processing.

Finely-tuned gamma (FTG) oscillations can be recorded from cortex or the subthalamic nucleus (STN) in patients with Parkinson's disease (PD) on dopaminergic medication, and have been associated with dyskinesias.

Exploratory analyses showed that higher anti-dopaminergic medication dosage was associated with a decreased response to oxytocin, consistent with previous findings in men.

Two clinical diagnostic confidence levels were used, possible PD (PossPD, never treated or not responsive) and probable PD (ProbPD, 2/3 cardinal clinical signs and responsive to dopaminergic medications).

Here, we illustrate the importance of personalizing non-pharmacological interventions, and also demonstrate the value of objectively evaluating the effects of dopaminergic medication.

Although animal studies and studies on Parkinson’s disease (PD) suggest that dopamine deficiency slows the pace of the internal clock, which is corrected by dopaminergic medication, timing deficits in parkinsonism remain to be characterized with diverse findings.

CONCLUSIONS The facilitatory effect of SICI on SICF is absent in PD OFF, but is restored with dopaminergic medication.

We tested three groups: individuals with PD under dopaminergic medication, an age-matched control group, and a group of young healthy adults.

However, STN-DBS and dopaminergic medications were shown to exert subtle yet significant opposing effects on the ability to learn from negative consequences.

Correlation of CSF or serum LPO and MDS-UPDRS, dopaminergic medication, and other clinical parameters was examined.

2 years), under dopaminergic medication, and 21 controls (62.

INTRODUCTION Neuroleptic malignant syndrome (NMS) is a severe and potentially lethal disorder due to an adverse reaction to dopamine receptor antagonism or the rapid withdrawal of dopaminergic medications.

Postoperative apathy cannot always be related to a dose reduction of dopaminergic medication and stimulation itself may play a role.

Standard treatment of Parkinson’s disease involves the dopaminergic medications.

The hallmark neuropathophysiological changes that occur in PD, plus the association between exposure to dopaminergic medications and certain psychiatric disorders, suggest a neurobiological basis for many psychiatric symptoms, although psychological factors are involved as well.

Results remained significant when controlling for motor improvement and dopaminergic medication withdrawal.

Patients with Parkinson’s disease (PD) are at an increased risk for delirium which may be underdiagnosed due to phenomenological overlap between delirium and chronic neuropsychiatric features of PD or side effects of dopaminergic medication.

Background: Balance impairment in Parkinson’s disease (PD) improves only partially with dopaminergic medication.

Purpose of ReviewTo address variation in the severity of gambling disorder, this review evaluates the contribution of mesocorticolimbic dopamine neurons to potential behavioral endophenotypes, the influence of individual differences in the dopamine system on gambling and related behaviors, and the possible role for dopaminergic medications in the treatment of gambling disorder.

We also tested whether attachment style, symptom severity, and anti-dopaminergic medication dosage moderated oxytocin effects.

49) and dopaminergic medications (OR 2.

In this work, we identified EEG-based altered resting-state cortical functional connectivity in Parkinson’s disease (PD) and examined effects of dopaminergic medication and electrical vestibular stimulation (EVS), a non-invasive brain stimulation (NIBS) technique capable of stimulating the BG and thalamus through vestibular pathways.

The volumes of activated tissue were analyzed to obtain significant stimulation clusters predictive of 4 clinical outcomes: improvements in bradykinesia, rigidity, tremor, and reduction of dopaminergic medication.

In addition, DLB is most often misdiagnosed as Parkinson’s disease (PD) when abnormalities of movement are present and due to the fact that, to many physicians, the movement symptoms of DLB may look similar to PD and may respond to dopaminergic medications.

However, particularly within the domain of short-term memory, it is unclear whether these impairments are masked, or caused, by patients’ dopaminergic medication.

Patients with more progressed disease and higher doses of dopaminergic medication performed significantly worse in the Comic Strip Task.

The authors investigated the association between postural impairment and changes in circadian rhythms in 24 PD subjects diagnosed with stages 1 to 3 on the Hoehn-Yard (HY) scale and regularly used dopaminergic medication for at least 1 year (experimental group – EG) and 24 healthy elderly individuals without a history of neurological impairment as the control group (CG).

We are not sure what is the upper limit of dopaminergic medication, especially the levodopa (LD) dosage, and how it is influenced by access and suitability to the various add-on and device-aided therapies (DAT).

Healthy older adults and PD patients were tested twice—on and off dopaminergic medication in counterbalanced order.

This theory was based on clinical observations which show that patients with RLS improve with dopaminergic medication [4].

Distinguishing stimulation-induced adverse effects from disease progression requires experience, a systematic approach to adjusting stimulation parameters and awareness of possible relationships with changes in dopaminergic medication.

In addition, the risk of developing freezing of gait (FOG) and longitudinal requirements for dopaminergic medications were examined.